A PDUFA date is the deadline the U.S. Food and Drug Administration (FDA) commits to when reviewing a new drug application. The name comes from the Prescription Drug User Fee Act, originally passed in 1992 and reauthorized roughly every five years.
When a biotech files a New Drug Application (NDA) or Biologics License Application (BLA), the FDA assigns a target action date — the date by which the agency commits to issuing a decision. That decision is one of three things:
- Approval — the drug is allowed on the U.S. market
- Complete Response Letter (CRL) — the FDA needs more from the sponsor before deciding
- Approval with restrictions — usually a black-box warning, REMS program, or limited label
Standard review timelines are 10 months. Priority Review trims that to 6 months, awarded for drugs that fill a significant unmet need.
Why traders watch PDUFA dates
PDUFA dates are binary, time-known-in-advance catalysts. On the day, a SMID-cap biotech with a single drug can move 30–90% in either direction. There’s very little middle ground — approval is what management has been pointing to for years, and a CRL invalidates the entire investment thesis until the sponsor can address the FDA’s concerns.
Because the dates are known months in advance, options markets price them in, but the magnitude of the eventual move is consistently larger than implied volatility suggests for smaller companies with binary outcomes.
Where PDUFA dates appear
Companies disclose PDUFA dates several ways:
- Press release announcing FDA acceptance of the NDA/BLA (typically also mentions the target action date)
- Form 8-K filing with the SEC, usually under Item 8.01 ("Other Events") or 7.01 ("Reg FD Disclosure")
- 10-K and 10-Q filings in the pipeline / catalysts narrative section
- Investor presentations at conferences (JPM Healthcare, ASCO, ASH, AACR)
Yeji ingests all of these and surfaces every confirmed PDUFA date in the catalyst calendar.
Common confusions
- PDUFA date vs. approval date. PDUFA is the deadline by which the FDA will decide. Approvals often come 1–3 days before the date. The FDA can also miss its PDUFA date if more time is needed (re-classified as "no action" — usually not great news).
- PDUFA date vs. AdCom date. An Advisory Committee meeting happens before the PDUFA date and is non-binding but heavily predictive. Not every NDA gets an AdCom — only the controversial ones.
- PDUFA extension. When the sponsor submits a major amendment late in the cycle, the FDA can extend the PDUFA date by three months. Extensions tend to be neutral-to-negative for the stock — the market wonders what changed.
How to use PDUFA dates in research
The date itself is the what and when. The why and the probability of success are what matters for investment work. That requires reading the clinical data, looking at comparable approvals in the same drug class, the FDA's historical posture on the indication, and the company's regulatory track record.
Yeji surfaces the PDUFA dates so you can spend your time on the analysis, not the calendar.